Jeffrey Jones
Chief Medical Officer CULLINAN THERAPEUTICS, INC.
Seminars
Wednesday 28th October 2026
Demonstrating Deep B-Cell Reset with CLN-978 by Translating Early Clinical Insights Moving Beyond Early Development
9:00 am
- Presenting emerging clinical data evaluating the safety, tolerability, and cytokine release syndrome profile of the CD19 x CD3 x HSA trispecific across autoimmune patient populations, establishing benchmarks for outpatient TCE administration
- Assessing the depth, durability, and tissue-level impact of B-cell depletion achieved through enhanced target engagement and extended half-life design, providing insight into the potential for sustained disease remission
- Translating clinical learnings on dosing, safety management, and biomarker evaluation into design principles for next-generation autoimmune T-cell engagers aimed at improving efficacy while minimizing treatment burden
Wednesday 28th October 2026
Panel Discussion: Translating First-Wave Autoimmune T-Cell Engager Clinical Data into Safer, More Effective Next-Generation Therapies
9:30 am
As the first generation of autoimmune T-cell engagers advances through clinical development, the field is beginning to generate critical insights into safety management, depth of immune-cell depletion, patient selection, and long-term disease control. The key challenge now is determining which clinical learnings will truly differentiate successful therapies. Join clinical leaders, translational scientists, and developers of leading autoimmune T-cell engager programs as they discuss how emerging clinical evidence is reshaping drug design and development strategies by:
- Defining the clinical benchmarks for success, evaluating what early efficacy, safety, cytokine release syndrome, and durability data reveal about the therapeutic potential of T-cell engagers across different autoimmune diseases and patient populations
- Understanding the drivers of durable immune reset, exploring how depth of depletion and target biology, contribute to longterm remission, and identifying the biomarkers needed to predict sustained clinical benefit
- Translating clinical learnings into next-generation molecule design, discussing how insights from first-wave programs are informing improvements in target selection, construct engineering, dosing strategies, administration routes, and patient monitoring to enhance efficacy while minimizing treatment burden and safety risks
